Biosynth Expands IVD Product Portfolio to Help Developers Improve Assay Performance and Supply Reliability
New recombinant materials, alternatives to animal-derived reagents and tunable enzyme substrates expand options for
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
![]()
New recombinant materials, alternatives to animal-derived reagents and tunable enzyme substrates expand options for assay development and optimization.
STAAD, ST. GALLEN, SWITZERLAND, November 16, 2026 /EINPresswire.com/ — Biosynth, a leading developer and supplier of critical raw materials and services for life sciences and diagnostics, is expanding its diagnostic materials offering to help in vitro diagnostic (IVD) developers manage material variability, explore sourcing alternatives and fine-tune assay performance. At MEDICA 2026 (Booth 3D66), the company will showcase monoclonal antibodies, recombinant materials, alternatives to traditional animal-derived reagents and tunable enzyme substrates.
Among the featured products are two hepatitis A virus (HAV) IgM monoclonal antibodies (mAb) developed as an alternative to native hepatitis A materials used in diagnostic applications. It provides IVD developers with a highly consistent, non-infectious alternative to native HAV materials, delivering lot-to-lot reproducibility, simplified regulatory handling, and a secure, scalable supply for long-term manufacturing.
Beyond the HAV antibody, the portfolio addresses several key needs in diagnostic development:
• Consistency and reproducibility. Recombinant materials for infectious disease and autoimmune testing, including rubella virus-like particles (VLPs), recombinant horseradish peroxidase (rHRP), recombinant rheumatoid factor IgM (rRF IgM) and autoimmune antigens, can provide greater control over material characteristics and help manage lot to lot variability.
• Alternative sourcing options. Synthetic alternatives to traditional animal derived reagents and materials for selected cell culture applications give developers additional options to assess against their technical requirements and sourcing needs.
• Assay performance optimization. Modular, tunable enzyme substrates allow developers to adjust substrate characteristics to specific assay requirements, helping refine sensitivity, specificity and signal intensity.
“Diagnostic developers need consistent materials, options that meet their specific assay requirements, and reliable access to critical components as programs advance toward commercialization,” said Philip Noone, CEO, Biologics Division. “By combining a broad portfolio with scientific expertise and global supply capabilities, we help customers address technical and sourcing challenges early and support them throughout development, not simply supply individual components.”
Diagnostic assays often combine materials with different chemical and biological requirements. Understanding how these components work together is important to achieving the required assay performance.
“Our expertise across biologics and specialty chemicals allows us to bring together complementary scientific disciplines to help customers solve complex material challenges,” said Holger Olbrück, Vice President, Strategic Accounts, Chemicals Division. “By understanding the specific requirements of an assay, we can help developers identify materials and solutions suited to their needs and then manufacture them reliably in the volumes the market demands.”
The portfolio and related capabilities will be featured at MEDICA 2026, Nov. 16-19, at Booth 3D66. Visitors can discuss material selection, assay requirements, sourcing and scale-up with the team.
MEDICA 2026 coincides with Biosynth’s 60th anniversary, marking six decades of scientific expertise and collaboration across the life sciences.
To learn more, visit https://www.biosynth.com/events/medica-2026.
About Biosynth
Biosynth is a global science and manufacturing partner providing critical raw materials, regulated inputs, intermediates and specialty research chemicals for pharmaceutical and biopharmaceutical companies, diagnostics and IVD developers, life science research, academia, and specialty and applied markets. Combining scientific expertise with a broad portfolio and global manufacturing capabilities, Biosynth provides products and custom solutions that help customers advance complex science from research and development through scale-up and commercial supply.
To learn more, follow Biosynth on LinkedIn or visit Biosynth.com.
Alyssa Ludvino
Biosynth
+1 888-681-2933
Visit us on social media:
LinkedIn
Legal Disclaimer:
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
![]()
Media gallery